Journal
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Volume 39, Issue 11, Pages 1823-1829Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.b16-00369
Keywords
cyclodextrin; octaarginine; Niemann-Pick disease type C; cholesterol; cell-penetrating peptide
Categories
Funding
- Japan Agency of Medical Research and Development (AMED)
- Grants-in-Aid for Scientific Research [16J11970] Funding Source: KAKEN
Ask authors/readers for more resources
Niemann Pick disease type C (NPC) is an autosomal recessive lysosomal storage disorder, which is an inherited disease characterized by the accumulation of unesterified cholesterol in endolysosomes. Recently, 2-hydroxypropyl-beta cyclodextrin (HP-beta-CyD) has been used for the treatment of NPC, and ameliorated a hepatosplenomegaly in the patients. However, to obtain the treatment efficacy, a high dose of HP-beta-CyD was necessary. Therefore, the decrease in dose by using active intracellular delivery system of beta-CyD to NPC cells is expected. In this study, to efficiently deliver beta-CyD to NPC-like cells, we newly synthesized octaarginine (R8)-appended-beta-CyD with a spacer of gamma-aminobutyric acid (R8-beta-CyD) and evaluated its cytotoxicity, intracellular distribution, endocytosis pathway and cholesterol-lowering effect in Npc1-trap-Chinese hamster ovary (CHO) cells, cholesterol-accumulated cells through the impairment of NPC1 function. R8-beta-CyD did not show cytotoxicity in the cells. In addition, Alexa568-labeled R8-beta-CyD was actively internalized into Npcl-trap-CHO cells, possibly through micropinocytosis. Notably, R8-beta-CyD significantly decreased intracellular cholesterol content compared with HP-beta-CyD. These results suggest that R8-beta-CyD may be a promising therapeutic agent for ameliorating cholesterol accumulation in NPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available